NCT07152769View on ClinicalTrials.gov

Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

December 31, 2028

Conditions
Advanced Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Iparomlimab and Tuvonralimab + GC

Iparomlimab and Tuvonralimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w

DRUG

Sintilimab + GC

Sintilimab: 5mg/kg, iv, q3w; Gemcitabine: 1000 mg/m2，iv，d1、d8，q3w; Cisplatin: 25 mg/m2，iv，d1、d8，q3w.

Trial Locations (1)

200062

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER